P113 | AUTOIMMUNE MANIFESTATIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A RETROSPECTIVE SINGLE-CENTER STUDY

Background. Chronic lymphocytic leukemia (CLL) often presents with autoimmune complications due to immune dysregulation. These manifestations can arise at different stages of the disease and across multiple organ systems, but their clinical impact and relevance for CLL management remain poorly defined. This retrospective study aimed to characterize autoimmune manifestations in CLL, the organ systems involved and timing of onset; we aimed to assess s their impact on the natural course, to disease progression, and the need to optimize management strategies. Methods. We analyzed data from about 1100 CLL consecutives patients; of those 150 patients have also autoimmune manifestations. In these patients, we classified the involved organ systems and the timing of onset relative to CLL diagnosis. Treatment responses for autoimmune diseases were assessed and their correlation with clinical variables was explored statistically. Results. Among the 150 CLL patients who developed autoimmune manifestations, the median age at CLL diagnosis was 65 years (range 40–92), with a slight male predominance (52.7%). Most patients (56.1%) were diagnosed at early disease stages (Rai 0 or Binet A). Autoimmune complications affected various organ systems. Hematological manifestations were the most frequent (32%), followed by rheumatological (28.7%), endocrinological and dermatological (9.3% each), neurological and gastroenterological (8% each), nephrological (3.3%), and hemorrhagic (1.3%) complications. Autoimmune manifestations were diagnosed before CLL in 72 patients (47,68%), concurrently with in 25 patients (16.55%), and after CLL in 54 patients (35,76%). No significant associations were found between the timing or the organ system involved and treatment response. Conclusions. Autoimmune manifestations in CLL are frequent and involve multiple organ systems. Our findings suggest that neither the affected organ system nor the timing of onset influences treatment outcomes, emphasizing the importance of early detection and individualized management strategies.